Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation

Cardiology in Review

Volumn 12, Issue 4, 2004, Pages 201-221

  Qasqas, Shadi A ^a   McPherson, Camille ^b   Frishman, William H ^c,e   Elkayam, Uri ^d  

^a BARNES JEWISH HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antiarrhythmics; Anticoagulants; Antihyperlipidemics; Antihypertensives; Cardiovascular drugs; Lactation; Pregnancy

Indexed keywords

ACEBUTOLOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; DIGITOXIN; DIGOXIN; DISOPYRAMIDE; ESMOLOL; FIBRINOLYTIC AGENT; FLECAINIDE; HYPOCHOLESTEROLEMIC AGENT; LIDOCAINE; METOPROLOL; MEXILETINE; NADOLOL; PINDOLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TOCAINAMIDE; UNINDEXED DRUG;

APNEA; BRADYCARDIA; BREAST FEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL TERATOGENESIS; CLINICAL PHARMACOLOGY; DIGITALIS INTOXICATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG TRANSPORT; EMBRYO DEVELOPMENT; FETUS DEATH; FETUS DEVELOPMENT; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTHYROIDISM; INTRAUTERINE GROWTH RETARDATION; JAUNDICE; LABOR COMPLICATION; LACTATION; LEARNING DISORDER; LUNG EDEMA; LUPUS ERYTHEMATOSUS; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; PERINATAL ASPHYXIA; PHARMACOKINETICS; PLACENTAL TRANSFER; POLYCYTHEMIA; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; RESPIRATORY DISTRESS; RETROPERITONEAL FIBROSIS; REVIEW; RISK BENEFIT ANALYSIS; SMALL FOR DATE INFANT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TREMOR; VERTIGO; VOMITING;

ABNORMALITIES, DRUG-INDUCED; ANTI-ARRHYTHMIA AGENTS; BREAST FEEDING; CARDIAC GLYCOSIDES; CARDIOVASCULAR SYSTEM; FEMALE; FETUS; HUMANS; INFANT; LACTATION; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 3042567310     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000102420.62200.e1     Document Type: Review

References (192)

1. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328-343.
2. Parbhoo SP, Johnston ID. Effects of oestrogens and progestogens on gastric secretion in patients with duodenal ulcer. Gut. 1966;7:612-618.
3. Parker WA. Effects of pregnancy on pharmacokinetics. In: Benet LZ, ed. Pharmacokinetic Basis for Drug Treatment. New York: Raven Press; 1984.
4. Widerhorn J., Rubin JN, Frishman WH, et al. Cardiovascular drugs in pregnancy. Cardiol Clin. 1987;5:651-674.
5. Krauer B, Krauer F, Hytten F. Drug prescribing in pregnancy. In: Lind T, ed. Current Reviews in Obstetrics and Gynecology. Edinburgh: Churchill Livingstone; 1984.
6. Burrow GN, Duffy TP, Kersey R, eds. Medical Complications During Pregnancy, 5th ed. Philadelphia: WB Saunders; 1999.
7. Metcalfe J, McAnulty JH, Ueland K. Burwell and Metcalfe's Heart Disease and Pregnancy: Physiology and Management, 2nd ed. Boston: Little, Brown; 1986:11-54.
8. Cole PL, Sutton MS. Normal cardiopulmonary adjustments to pregnancy: cardiovascular evaluation. Cardiovasc Clin. 1989;19:37-56.
9. Hemgren L, Ehrnebo M, Boreus LO. Drug binding to plasma proteins during human pregnancy and in the perinatal period. Studies on cloxacillin and alprenolol. Dev Pharmacol Ther. 1983;6:110-124.
10. Wood M, Wood AJ. Changes in plasma drug binding and α1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther. 1981;29:522-526.
11. Ralston DH. Perinatal pharmacology. In: Snider SM, Levinson G, eds. Anesthesiafor Obstetrics. Baltimore: Williams & Wilkins; 1987:50-58.
12. Rotmensch HH, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy. Ann Intern Med. 1983;98:487-497.
13. Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and the puerperium. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss; 1998:3-19.
14. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol. 1981;88:1-9.
15. Wadelius M, Dao E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62:400-407.
16. Levy G. Pharmacokinetics of fetal and neonatal exposure to drugs. Obstet Gynecol. 1981;58(suppl 5):9S-16S.
17. Howard FM, Hill JM. Drugs in pregnancy. Obstet Gynecol Surv. 1979;34:643-653.
18. Stern L. In vivo assessment of the teratogenic potential of drugs in humans. Obstet Gynecol. 1981;58(suppl 5):3S-8S.
19. Berlin CM Jr. Pharmacologic considerations of drug use in the lactating mother. Obstet Gynecol. 1981;58(suppl 5):17S-23S.
20. Schanker LS. Passage of drugs across body membranes. Pharmacol Gynecol. 1962;14:501-530.
21. Anderson PO. Drugs and breast feeding. In: Knoben JE, Anderson PO, eds. Handbook of Clinical Drug Data, 6th ed. Hamilton, IL: Drug Intelligence; 1988:157-184.
22. Okita GT, Gordon RB, Geiling EML. Placental transfer of radioactive digitoxin in rats and guinea pigs. Proc Soc Exp Biol Med. 1952;80:536-538.
23. Saarikoski S. Placental transmission and foetal distribution of 3H-ouabain. Acta Pharmacol Toxicol. 1980;46:272-282.
24. Rogers MC, Willerson JT, Goldblatt A, et al. Serum digoxin concentrations in the human fetus, neonate and infant. N Engl J Med. 1972;287:1010-1013.
25. Sherman JL, Locke RV. Transplacental neonatal digitalis intoxication. Am J Cardiol. 1960;6:834-837.
26. Potondi A. Congenital rhabdomyoma of the heart and intrauterine digitalis poisoning. J Forensic Sci. 1967;11:81-88.
27. Whitsett JA, Wallick ET. [3H] ouabain binding and Na+, K+-ATPase activity in human placenta. Am J Physiol. 1980;238:E38-E45.
28. Weaver JB, Pearson JF. Influence of digitalis on time of onset and duration of labour in women with cardiac disease. BMJ. 1973;3:519-520.
29. Steinberg I, Mitani GM, Harrrison EC, et al. Digitalis glycosides in pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss, Inc; 1998:426-431.
30. Gewitz M, Woolf P, Frishman WH, et al. Pediatric cardiovascular pharmacology. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:893-918.
31. Copel JA, Friedman AH, Kleinman CS. Management of fetal cardiac arrhythmias. Obstet Gynecol Clin North Am. 1997;24:201-211.
32. Ito S, Magee L, Smallhorn J. Drug therapy for fetal arrhythmias. Clin Perinatol. 1994;21:543-572.
33. Belhassen B, Pauzner D, Blieden D, et al. Intrauterine and postnatal atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation. 1982;66:1124-1128.
34. Loughnan PM. Digoxin excretion in human breast milk. J Pediatr. 1978;92:1019-1020.
35. Anderson JL, Harrison DC, Meffin PJ, et al. Antiarrhythmic drugs: clinical pharmacology and therapeutic uses. Drugs. 1978;15:271-309.
36. Spinnato JA, Shaver DC, Flinn GS, et al. Fetal supraventricular tachycardia in utero therapy with digoxin and quinidine. Obstet Gynecol. 1984;64:730-735.
37. Johnson WH, Dunnigan A, Fehr P, et al. Association of atrial flutter with orthodromic reciprocating fetal tachycardia. Am J Cardiol. 1987;59:374-375.
38. Whelan AJ. Pregnancy and medical therapeutics. In: McKenzie CR, Ewald GA, eds. Manual of Medical Therapeutics, 28th ed. Boston: Little, Brown; 1995:15
39. Hill LM, Malkasian GD. The use of quinidine sulfate throughout pregnancy. Obstet Gynecol. 1979;54:366-368.
40. Shotan A, Hurst A, Widerhorn J, et al. Antiarrhythmic drugs during pregnancy and lactation. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss, Inc; 1998:373
41. Rosa F. Personal communication. FDA: 1993. In: Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 4th ed. Baltimore: Williams & Wilkins; 1994:284,693,759.
42. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw Hill; 2001:933-970.
43. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137-150.
44. Dumesic DA, Silverman NH, Tobias S, et al. Transplacental cardioversion of fetal supraventricular tachycardia with procainamide. N Engl J Med. 1982;307:1128-1131.
45. Given BD, Phillippe M, Sanders SP, et al. Procainamide cardioversion of fetal supraventricular tachyarrhythmia. Am J Cardiol. 1984;53:1460-1461.
46. Battiste CE, Neff TW, Evans JF, et al. In utero conversion of supraventricular tachycardia with digoxin and procainamide at 17 weeks' gestation. Am J Perinatol. 1992;9:302-303.
47. Pittard WB III, Glazier H. Procainamide excretion in human milk. J Pediatr. 1983;102:631-633.
48. Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics, and projected consequences. Clin Pharmacokinet. 1980;5:1-66.
49. Luoma PV, Kujala PA, Juustila HJ, et al. Efficacy of intravenous disopyramide in the termination of supraventricular arrhythmias. J Clin Pharmacol. 1978;18:293-301.
50. Shaxted EJ, Milton PJ. Disopyramide in pregnancy: a case report. Curr Med Res Opin. 1979;6:70-72.
51. Leonard RF, Braun TE, Levy AM. Initiation of uterine contractions by disopyramide during pregnancy. N Engl J Med. 1978;299:84-85.
52. Tadmor OP, Keren A, Rosenak D, et al. The effect of disopyramide on uterine contractions during pregnancy. Am J Obstet Gynecol. 1990;162:482-486.
53. Abbi M, Kriplani A, Singh B. Preterm labor and accidental hemorrhage after disopyramide therapy in pregnancy. A case report. J Reprod Med. 1999;44:653-655.
54. Echizen H, Nakura M, Saotome T, et al. Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers. Br J Clin Pharmacol. 1990;29:423-430.
55. Ellsworth AJ, Horn JR, Raisys VA, et al. Disopyramide and N-monodesalkyl-disopyramide in serum and breast milk. Drug Intell Clin Pharm. 1989;23:56-57.
56. Barnett DB, Hudson SA, McBurney A. Disopyramide and its N-monodesalkyl metabolite in breast milk. Br J Clin Pharmacol. 1982;14:310-312.
57. Biehl D, Shnider SM, Levinson G, et al. Placental transfer of lidocaine: effects of fetal acidosis. Anesthesiology. 1978;48:409-412.
58. Juneja MM, Ackerman WE, Kaczorowski DM, et al. Continuous epidural lidocaine infusion in the parturient with paroxysmal ventricular tachycardia. Anesthesiology. 1989;71:305-308.
59. Tucker GT, Boyes RN, Bridenbaugh PO, et al. Binding of anilide-type local anesthetics in human plasma. II. Implications in vivo, with special reference to transplacental distribution. Anesthesiology. 1970;33:304-314.
60. Shnider SM, Way EL. Plasma levels of lidocaine (Xylocaine) in mother and newborn following obstetrical conduction anesthesia: clinical applications. Anesthesiology. 1968;29:951-958.
61. Brown WU, Bell GC, Lurie AO, et al. Newborn blood levels of lidocaine and mepivacaine in the first postnatal day following maternal epidural anesthesia. Anesthesiology. 1975;42:698-707.
62. Shnider SM, Way EL. The kinetics of transfer of lidocaine (Xylocaine) across the human placenta. Anesthesiology. 1968;29:944-950.
63. Kuhnert BR, Knapp DR, Kuhnert PM, et al. Maternal, fetal, and neonatal metabolism of lidocaine. Clin Pharmacol Ther. 1979;26:213-220.
64. Kim WY, Pomerance JJ, Miller AA. Lidocaine intoxication in a newborn following local anesthesia for episiotomy. Pediatrics. 1979;64:643-645,
65. De Praeter C, Vanhaesebrouck P, De Praeter N, et al. Episiotomy and neonatal lidocaine intoxication. Eur J Pediatr. 1991;150:685-686.
66. Brown WU Jr, Bell GC, Alper MH. Acidosis, local anesthetics, and the newborn. Obstet Gynecol. 1976;48:27-30.
67. Burney RG, DiFazio CA, Foster JA. Effects of pH on protein binding of lidocaine. Anesth Analg. 1978;57:478-480.
68. Kileff MB, James FM III, Dewan D, et al. Neonatal neuro-behavioral responses after epidural anesthesia for cesarean section with lidocaine and bupivacaine. Anesthesiology. 1983;57:A403.
69. Scanlon JW, Ostheimer GW, Lurie AO, et al. Neurobehavioral responses and drug concentrations in newborns after maternal epidural anesthesia with bupivacaine. Anesthesiology. 1976;45:400-405.
70. Campbell RW. Mexiletine. N Engl J Med, 1987;316:29-34.
71. Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet. 1980;2:647-648.
72. Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol. 1987;157:446-447.
73. Gregg AR, Tomich PG. Mexiletine use in pregnancy. J Perinatol. 1988;8:33-35.
74. Currie P, Ramsdale DR. Paranoid psychosis induced by tocainide. BMJ. 1984;288:606-607.
75. Holmes B, Brogden RN, Heel RC, et al. Tocainide: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1983;26:93-123.
76. Roden DM, Woosley RL. Tocainide. N Engl J Med. 1986;315:41-45.
77. Drug Information for the Health Care Professional, vols 1A & 1B (12th ed). Rockville, MD: United States Pharmacopeial Convention; 1992.
78. Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J. 1992;67:266-268.
79. Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990;119:700-702.
80. Wren C, Hunter S. Maternal administration of flecainide to terminate and suppress fetal tachycardia. BMJ. 1988;296:249.
81. Allan LD, Chita SK, Sharland GK, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991;65:46-48.
82. Perry JC, Ayres NA, Carpenter RJ Jr. Fetal supraventricular tachycardia treated with flecainide acetate. J Pediatr. 1991;118:303-305.
83. Vautier-Rit S, Dufour P, Vaksmann G, et al. Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases. Gynecol Obstet Fertil. 2000;28:729-737.
84. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999;20:85-94.
85. Macphail S, Walkinshaw SA. Fetal supraventricular tachycardia: detection by routine auscultation and successful in-utero management. Case report. Br J Obstet Gynaecol. 1988;95:1073-1076.
86. Brunozzi LT, Meniconi L, Chiocchi P, et al. Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient. Br J Clin Pharmacol. 1988;26:489-490.
87. Libardoni M, Piovan D, Busato E, et al. Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk. Br J Clin Pharmacol. 1991;32:527-528.
88. Frishman WH. Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:67-97.
89. Eliahou HE, Silverberg DS, Reisin E, et al. Propranolol for the treatment of hypertension in pregnancy. Br J Obstet Gynaecol. 1978;85:431-436.
90. Sandstrom B. Adrenergic beta-receptor blockers in hypertension of pregnancy. Clin Exp Hypertens. 1982;B1:127-141.
91. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation. 1998;97:451-456.
92. Sherif IH, Oyan WT, Bosairi S, et al. Treatment of hyperthyroidism in pregnancy. Acta Obstet Gynecol Scand. 1991;70:461-463.
93. Turner GM, Oakley CM, Dixon HG. Management of pregnancy complicated by hypertrophic obstructive cardiomyopathy. BMJ. 1968;4:281-284.
94. Teuscher A, Bossi E, Imhof P, et al. Effect of propranolol on fetal tachycardia in diabetic pregnancy. Am J Cardiol. 1978;42:304-307.
95. Bott-Kanner G, Schweitzer A, Reisner SH, et al. Propranolol and hydralazine in the management of essential hypertension in pregnancy. Br J Obstet Gynaecol. 1980;87:110-114.
96. Ngo A, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: McGraw Hill; 1997:1309-1346.
97. O'Hare MF, Kinney CD, Mumaghan GA, et al. Pharmacokinetics of propranolol during pregnancy. Eur J Clin Pharmacol. 1987;27:583-587.
98. Livingstone I, Craswell PW, Bevan EB, et al. Propranolol in pregnancy: three year prospective study. Clin Exp Hypertens. 1983;2:341-350.
99. Taylor EA, Turner P. Antihypertensive therapy with propranolol during pregnancy and lactation. Postgrad Med J. 1981;57:427-430.
100. Gladstone GR, Hordof A, Gersony WM. Propranolol administration during pregnancy: effects on the fetus. J Pediatr. 1975;86:962-964.
101. Tunstall MB. The effect of propranolol on the onset of breathing at birth. Br or Anaesth. 1969;41:792.
102. Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979;135:485-489.
103. Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol. 1991;98:244-248.
104. Smith MT, Livingstone I, Hooper WD, et al. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma. Ther Drug Monit. 1983;5:87-93.
105. Oakes GK, Walker AM, Ehrenkranz RA, et al. Effects of propranolol infusion on the umbilical and uterine circulations of pregnant sheep. Am J Obstet Gynecol. 1976;126:1038-1042.
106. Oakley GD, McGarry K, Limb DG, et al. Management of pregnancy in patients with hypertrophic cardiomyopathy. BMJ. 1979;1:1749-1750.
107. Cottrill CM, McAllister RG Jr, Gettes L, et al. Propranolol therapy during pregnancy, labor and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr. 1977;91:812-814.
108. Karlberg B, Lundberg D, Aberg H. Excretion of propanolol in human breast milk. Acta Pharmacol Toxicol. 1974;34:222-224.
109. Bauer JH, Pape B, Zajicek J, et al. Propranolol in human plasma and breast milk. Am J Cardiol. 1979;43:860-862.
110. Hurst AK, Hoffman K, Frishman WH. The use of β-adrenergic blocking agents in pregnancy and lactation. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss, Inc; 1998:357-369.
111. Fox RE, Marx C, Stark AR. Neonatal effects of maternal nadolol therapy. Am J Obstet Gynecol. 1985;152:1045-1046.
112. Devlin RG, Duchin KL, Fleiss PM. Nadolol in human serum and breast milk. Br J Clin Pharmacol. 1981;12:393-396.
113. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 5th ed. Baltimore: Williams & Wilkins; 1998:765.
114. Rasanen J, Jouppila P. Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Eur J Obstet Gynecol Reprod Biol. 1995;62:195-201.
115. Ellenbogen A, Jaschevatzky O, Davidson A, et al. Management of pregnancy-induced hypertension with pindolol-comparative study with methyldopa. Int J Gynaecol Obstet. 1986;24:3-7.
116. Dubois D, Petitcolas J, Temperville B, et al. Treatment of hypertension in pregnancy with β-adrenoceptor antagonist. Br J Clin Pharmacol. 1982;13(suppl 2):375S-378S.
117. Schrefer J, Nissen D, et al, eds. Mosby's GenRx, 11th ed. St. Louis: Mosby, Inc; 2001.
118. Lindeberg S, Sandstrom B, Lundborg P, et al. Disposition of the adrenergic blocker metoprolol in the late pregnant woman, the amniotic fluid, the cord blood, and the neonate. Acta Obstet Gynecol Scand. 1984;118(suppl):61- 64.
119. Hogstedt S, Lindberd B, Peng DR, et al. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther. 1985;37:688-692.
120. Frigo P, Eppel W, Frank A, et al. Management of supraventricular tachycardia during hexoprenaline therapy for preterm labour: benefit of cardioselective beta blockade? Gynecol Obstet Invest. 1995;39:212-214.
121. Kaaja R, Hiilesmaa V, Holma K, et al. Maternal anti-hypertensive therapy with beta-blockers associated with poor outcome in very low-birth weight infants. Int J Gynaecol Obstet. 1992;38:195-199.
122. Rubin PC, Butters L, Low RA, et al. Atenolol in the treatment of essential hypertension during pregnancy. Br J Clin Pharmacol. 1982;14:279-281.
123. Reynolds B, Butters L, Evans J, et al. First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child. 1984;59:1061-1063.
124. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541-547.
125. Satge D, Sasco AJ, Col JY, et al. Antenatal exposure to atenolol and retroperitoneal fibromatosis. Reprod Toxicol. 1997;11:539-541.
126. Hurst A, Shotan A, Hoffman K, et al. Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. Pharmacotherapy. 1998;18:840-846.
127. Easterling TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol. 1999;93:725-733.
128. von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92.
129. Williams E, Morrissey J. A comparison of acebutolol with methyldopa in hypertensive pregnancy. Pharmatherapeutica. 1983;3:487-491.
130. Boutroy MJ, Bianchetti G, Dubruc C, et al. To nurse when receiving acebutolol: is it dangerous for the neonate? Eur J Clin Pharmacol. 1986;30:737-739.
131. Gilson GJ, Knieriem KJ, Smith JF, et al. Short-acting beta-adrenergic blockade and the fetus. A case report. J Reprod Med. 1992;37:277-279.
132. O'Hare MF, Murnaghan GA, Russell CJ, et al, Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol. 1980;87:814-820.
133. Sonesson SE, Fouron JC, Wesslen-Eriksson E, et al. Foetal supraventricular tachycardia treated with sotalol. Acta Paediatr. 1998;87:584-587.
134. Lisowski LA, Verheijen PM, Benatar AA, et al. Atrial flutter in the perinatal age group: diagnosis, management and outcome. J Am Coll Cardiol. 2000;35:771-777.
135. Hackett LP, Wojnar-Horton RE, Dusci LJ, et al. Excretion of sotalol in breast milk [Letter]. Br J Clin Pharmacol 1990;29:277-278.
136. de Swiet M. Maternal blood pressure and birthweight. Lancet. 2000;355:81-82.
137. McKenna WJ, Harris L, Rowland E, et al. Amiodarone therapy during pregnancy. Am J Cardiol. 1983;51:1231-1233.
138. Pitcher D, Leather HM, Storey GCA, et al. Amiodarone in pregnancy. Lancet. 1983;1:597-598.
139. Gembruch U, Manz M, Bald R, et al. Repeated intravascular treatment with amiodarone in a fetus with refractory supraventricular tachycardia and hydrops fetalis. Am Heart J. 1989;118:1335-1338.
140. Amour P, Seyral P, Llurens M, et al. Amiodarone and digoxin for refractory fetal tachycardia. Am J Cardiol. 1987;59:166-167.
141. Penn IM, Barrett PA, Pannikote V, et al. Amiodarone in pregnancy. Am J Cardiol. 1985;56:196-197.
142. Valensise H, Civitella C, Garzetti GG, et al. Amiodarone treatment in pregnancy for dilatative cardiomyopathy with ventricular malignant extrasystole and normal maternal and neonatal outcome. Prenat Diagn. 1992;12:705-708.
143. Strunge P, Frandsen J, Andreasen F. Amiodarone during pregnancy. Eur Heart J. 1988;9:106-109.
144. Robson D, Jeeva RMV, Storey GCA, et al. Use of amiodarone during pregnancy, Postgrad Med J. 1985;61:75-77,
145. DeWolf D, DeSchepper J, Verhaaren H, et al. Congenital hypothyroidism goiter and amiodarone. Acta Paediatr Scand. 1988;77:616-618.
146. Widerhom J, Bhandari AK, Bughi S, et al. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am Heart J. 1991;122:1162-1165.
147. Laurent M, Betremieux P, Biron Y, et al. Neonatal hypothyroidism after treatment by amiodarone during pregnancy. Am J Cardiol. 1987;60:142.
148. Magee LA, Downar E, Sermer M, et al. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol. 1995;172:1307-1311.
149. De Catte L, De Wolf D, Smitz J, et al. Fetal hypothyroidism as a complication of amiodarone treatment of persistent fetal supraventricular tachycardia. Prenat Diagn. 1994;14:762-765.
150. Matsumura LK, Born D, Kunii IS, et al. Outcome of thyroid function in newborns from mothers treated with amiodarone. Thyroid. 1992;2:279-281.
151. Ovadia M, Brito M, Hoyer GL, et al. Human experience with amiodarone in the embryonic period. Am J Cardiol. 1994;73:316-317.
152. Magee L, Nulman I, Rovert JF. Neurodevelopment after in utero amiodarone exposure. Neurotoxicol Teratol. 1999;21:261.
153. Bartalena L, Bogazzi F, Braverman LE. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24:116-130.
154. Grosso S, Berardi R, Cioni M, et al. Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases. J Endocrinol Invest. 1998;21:699-702.
155. Gutgesell M, Overholt E, Boyle R. Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report. Am J Perinatol. 1990;7:144-145.
156. Byerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20:552-554.
157. Klein V, Repke JT. Supraventricular tachycardia in pregnancy: cardioversion with verapamil. Obstet Gynecol 1984;63(suppl 3):16S-18S.
158. Orlandi C, Marlettini MG, Cassani A, et al. Treatment of hypertension during pregnancy with the calcium antagonist verapamil. Curr Ther Res. 1986;39:884-893.
159. Belfort MA, Anthony J, Buccimazza A, et al. Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol. 1990;75:970-974.
160. Belfort M, Akovic K, Anthony J, et al. The effect of acute volume expansion and vasodilatation with verapamil on uterine and umbilical artery Doppler indices in severe preeclampsia. J Clin Ultrasound. 1994;22:317-325.
161. Ulmsten U. Inhibition of myometrial hyperactivity by Ca antagonists. Dan Med Bull. 1979;26:125-126.
162. Kanzaki T, Murakami M, Kobayashi H, et al. Hemodynamic changes during cardioversion in utero: a case report of supraventricular tachycardia and atrial flutter. Fetal Diagn Ther. 1993;8:37-44.
163. Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound, 1985;13:265-273.
164. Andersen HJ. Excretion of verapamil in human milk. Eur J Clin Pharmacol. 1983;25:279-280.
165. Miller MR, Withers R, Bhamra R, et al. Verapamil and breast-feeding. Eur J Clin Pharmacol. 1986;30:125-126.
166. Inoue H, Unno N, Ou M-C, et al. Level of verapamil in human milk. Eur J Clin Pharmacol. 1984;26:657-658.
167. Holbrook RH Jr, Gibson RN, Voss EM. Tocolytic and cardiovascular effects of the calcium antagonist diltiazem in the near-term pregnant rabbit. Am J Obstet Gynecol. 1988;159:591-595.
168. Downing SJ, Edwards D, Hollingsworth M. Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. Br J Pharmacol. 1987;91:735-745.
169. Okada M, Inoue H, Nakamura Y, et al. Excretion of diltiazem in human milk. N Engl J Med. 1985;312:992-993.
170. Frishman WH, Sica DA. Calcium channel blockers, In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:105-130.
171. Childress CH, Katz VL. Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol. 1994;83:616-624.
172. Nootens M, Rich S. Successful management of labor and delivery in primary pulmonary hypertension. Am J Cardiol. 1993;71:1124-1125.
173. Pirhonen JP, Erkkola RU, Ekblad UU, et al. Single dose of nifedipine in normotensive pregnancy: nifedipine concentrations, hemodynamic responses, and uterine and fetal flow velocity waveform. Obstet Gynecol. 1990;76:807-811.
174. Mari G, Kirshon B, Moise KJ, et al. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol. 1989;161:1514-1518.
175. Moretti NM, Fairlie FM, Akl-S, et al. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol. 1990;163:1844-1848.
176. Lindow SW, Davies N, Davey DA, et al. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynaecol. 1988;96:1276-1281.
177. Prevost RR, Akl SA, Whybrew WD, et al. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy. 1992;12:174-177.
178. Manninen AK, Juhakoski A. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine. Int J Clin Pharmacol Res. 1991;11:231-236.
179. Ferguson JE Jr, Schutz T, Pershe R, et al. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol. 1989;161:1485-1490.
180. Fenakel K, Fenakel G, Appelman Z, et al. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol. 1991;77:331-337.
181. Bracero LA, Leikin E, Kirschenbaum N, et al. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Am J Perinatol. 1991;8:365-369.
182. Ferguson JE Jr, Dyson DC, Schutz T, et al. A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. Am J Obstet Gynecol. 1990;163:105-111.
183. Kupferminc M, Lessing JB, Yaron Y, et al. Nifedipine versus ritodrine for suppression of preterm labor. Br J Obstet Gynaecol. 1993;100:1090-1094.
184. Tsatsaris V, Papatsonis D, Goffinet F, et al. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gynecol. 2001;97:840-847.
185. Khedun SM, Maharaj B, Moodley J. Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing? Paediatr Drugs. 2000;2:419-436.
186. Maigaard S, Forman A, Andersson KE, et al. Comparison of the effects of nicardipine and nifedipine on isolated human myometrium. Gynecol Obstet Invest. 1983;16:354-366.
187. Carbonne B, Jannet D, Touboul C, et al. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1992;81:908-914.
188. Jannet D, Carbonne B, Sebban E, et al. Nicardipine versus metoprolol in the treatment o f hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol. 1994;84:354-359.
189. Podolsky SM, Varon J. Adenosine use during pregnancy. Ann Emerg Med. 1991;29:1027-1028.
190. Mason BA, Ricci-Goodman J, Koos BJ. Adenosine in the treatment of maternal paroxysmal supraventricular tachycardia. Obstet Gynecol. 1992;80:478-480.
191. Chakhtoura N, Angioli R, Yasin S. Use of adenosine for pharmacological cardioversion of SVT in pregnancy. Prim Care. 1998;5:154.
192. Leffier S, Johnson DR. Adenosine use in pregnancy: lack of effect on fetal heart rate. Am J Emerg Med. 1992;10:548-549.